Wednesday , March 29 2017
Home / 2016 / July

Monthly Archives: July 2016

NIH-Led Researchers Develop Software that could Facilitate Drug Development

A team of researchers led by a National Institutes of Health investigator, Teresa Przytycka, Ph.D., has developed a new software tool called AptaTRACE that could be an important advance for drug developers and other scientists who want to identify molecules that bind with high precision to targets of interest. “This …

Read More »

Editas Medicine Enters Collaboration with Italian Gene Therapy Institute

CAMBRIDGE, Mass., July 28, 2016 (GLOBE NEWSWIRE) — Editas Medicine, Inc.(NASDAQ:EDIT), a leading genome editing company, and Fondazione Telethon and Ospedale San Raffaele, which operate a joint research collaboration known as the San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), have entered into a scientific collaboration to research and develop …

Read More »

Triple-Therapy Patch Delivers Local Treatment, Prevents Recurrence in Colon Cancer Model

Investigators at Brigham and Women’s Hospital have developed a hydrogel patch that can adhere to tumors in a preclinical model of colon cancer, delivering a local, combination treatment as the elastic gel breaks down over time. The new technique may allow clinicians to one day use diagnostic colonoscopy equipment to …

Read More »

Penn Study Verifies Human Gene Therapy in Model of Rare Metabolic Disorder

PHILADELPHIA — Researchers are closer to finding a better way to treat children with a rare metabolic disorder called MPS I. It is caused by a deficiency of the key enzyme IDUA needed to break down complex sugars in cells. MPS I eventually leads to the abnormal accumulation of sugar …

Read More »

Pfizer’s Xeljanz Demonstrates Positive Results in its Late-Stage Ulcerative Colitis Study

NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) announced today top-line results from Oral Clinical Trials for tofAcitinib in ulceratiVE colitis (OCTAVE) Sustain, the third Phase 3 study of XELJANZ® (tofacitinib citrate) being investigated in patients with moderately to severely active ulcerative colitis (UC). OCTAVE Sustain is a 52 week study that evaluated …

Read More »

FDA Grants Fast Track Status to Shire’s Treatment for Patients who have NASH with Liver Fibrosis

Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation for SHP626 (volixibat) for an investigational treatment of adults who have nonalcoholic steatohepatitis (NASH) with liver fibrosis. Shire is developing SHP626 as a once daily, orally-administered inhibitor of …

Read More »

Pfizer and Western Oncolytics Collaborate to Investigate Novel Oncolytic Virus Technology

NEW YORK & CLEVELAND–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) and Western Oncolytics announced today that they have entered into a development collaboration, license and option agreement to advance Western Oncolytics’ novel oncolytic vaccinia virus, WO-12. Oncolytic viruses are viruses engineered to kill cancer cells while sparing healthy cells, which subsequently elicits anti-cancer …

Read More »

Sanofi’s Adlyxin Receives FDA Approval for Treatment of Type 2 Diabetes

PARIS, July 27, 2016 /PRNewswire/ — Sanofi announced today that the U.S. Food and Drug Administration (FDA) approved Adlyxin™ (lixisenatide), a once-daily mealtime GLP-1 receptor agonist injection indicated as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes. “The approval of Adlyxin reaffirms our …

Read More »

2016 World Hepatitis Day

The “Elimination” theme of this year’s World Hepatitis Day – coming up on July 28, 2016 – highlights the vision of lessening the world burden of hepatitis. The organizers note that “Every action is an action towards elimination of viral hepatitis.” This theme is echoed by the first-ever establishment by the …

Read More »

Cytokinetics and Astellas Expand Collaboration into ALS

SOUTH SAN FRANCISCO, Calif. and TOKYO, July 27, 2016 (GLOBE NEWSWIRE) — Cytokinetics, Inc.(Nasdaq:CYTK) (“Cytokinetics”) and Astellas Pharma Inc. (TSE:4503) (“Astellas”) today announced that Cytokinetics and Astellas have expanded their collaboration in skeletal muscle activators to include amyotrophic lateral sclerosis (ALS).  Through this expansion, Cytokinetics has granted Astellas an option …

Read More »